Health, Medical, Fitness, Beauty Businesses for Sale in Irvine, California
Irvine, California
Health, Medical, Fitness, Beauty
4 results for "Health, Medical, Fitness, Beauty" businesses in "Irvine, California"
Irvine, California
Health, Medical, Fitness, Beauty
4 results for "Health, Medical, Fitness, Beauty" businesses in "Irvine, California"
Save this Search
Search Saved!
Name Your Search
Irvine, California
In-Network Lab: Medicare, Medi-Cal, PPOs, Many Medicaids
$ 3,300,000
Fully licensed high-complexity CLIA-certified clinical laboratory with CAP accreditation, Medicare, and Medi-Cal provider status. This turnkey operation offers a rare opportunity for immediate activation or relocation to the buyer’s preferred site. Price: $2,500,000. Established: 2025 Certifications: CLIA (High Complexity), CAP, 1- Aetna :commercial and Medicare advantage 2- Anthem Blue Cross: nationwide 3- United Health Care 4- Workers compensation 5- Multiplan in process 6- Medicare 7- Medi-Cal 8-Ohio , Colorado and Alaska medicaid in process Lease: $4,500/month (all-inclusive). Security Deposit: $13,392. Facility Size: 2,400 sq. ft. Lease Term: Through October 2026 (renewal option available) Relocation: Moving the lab to the buyer’s location is possible—and preferred for qualified buyers Reason for Sale: Owner is pursuing another career opportunity
Orange County, California
Upscale Beauty Salon So OC 22 Hair Stations + All Other Services
$ 1,250,000
CF : $ 400,000
This upscale beauty salon, located in the heart of South Orange County, California, presents an incredible opportunity to step into a thriving business. The salon is fully equipped, offering a comprehensive range of beauty services. The salon includes 22 fully rented hair stations, generating consistent income at competitive rates of $450 per week. Additionally, there are two manicurist stations, each bringing in $300 per week, and three aesthetician stations rented at $450 per week. Currently, one of these stations is rented, leaving two available for potential additional income. For more specialized beauty services, the salon also includes two eye threading stations (both currently available), and a makeup room which is being utilized. Beyond services, the salon also offers incredible products, jewelry, and beauty supplies. The sale of this salon is a turnkey opportunity, including full support for a smooth transition. The seller is committed to assisting in transferring the business, accounts, brand name, employees, independent contractors, books, and the website, providing guidance as long as needed post-sale. This is a rare chance to own a fully operational salon in a prosperous location. For more details about this very profitable business, please contact the broker at 714-363-0440 or ubi@ubibiz.com.
Irvine, California
Pharmaceutical Company - Targeting Drug Delivery
$ 20,000,000
Patented Universal Tumor-Targeting Drug Delivery Platform Co. This pharmaceutical company has developed and patented a universal tumor-targeting drug-delivery platform that can improve the safety and efficacy of many existing chemo treatments, with the ability to target numerous different types of cancer. The technology encapsulates existing FDA-approved drugs inside lipid nanoparticles (liposomes or emulsions) coated with patented human-sourced antinuclear antibodies (ANA). The lipid nanoparticle provides long-term storage stability of the drug and controlled release of the drug over time at body-temperature, and is expected to improve the safety and efficacy profile of the drug, including passive accumulation at the tumor while not harming normal tissues. The Company's ANA, sourced from lupus patients, binds to nuclear material present in abundance in areas of necrosis (dead / ruptured cells) present in and around all solid tumors, thus anchoring the drug-filled nanoparticles at the tumor where the nanoparticle is designed to slowly release the drug directly on the tumor for more effect. As the Company's ANA is not tumor-marker specific, but rather targets necrosis present in solid tumors, the technology is designed to "universally" target many different types of cancer including breast cancer, lung, ovarian, colon, prostate, etc., as well as rare childhood cancers. The Company completed a successful proof-of-concept study at Children's Hospital using Ewing's Sarcoma transplanted in immunodeficient mice. Treatment with the Company's forumlation significantly inhibited tumor growth and extended survival times compared to control mice receiving no treatment or treatment with plain liposomal doxorubicin. The Company has been granted Orphan Drug Designation by the FDA on 2 of the lead drug formulations, providing FDA fee waivers, priority review, and 7-years exclusivity upon market approval. The orphan pathway also enables the potential for New Drug Approval after successful completion of Phase 2 studies, with Phase III data collected while in the market, thus significantly lowering the time and cost to market approval. This same drug inside the Company's tumor targeting delivery system will likely have potential to treat other pediatric cancers, and/or cancers in larger adult populations. As the Company's platform and ANA has the potential to improve the safety and efficacy of many existing FDA approved drugs or even compounds in development, the Company anticipates the potential for multiple licensing agreements with multiple pharmaceutical companies seeking to improve their existing portfolio and extend patient life as they advance into clinical stage. And as it may be possible to file for New Drug Approval following successful Phase II studies, the Company anticipates licensing potential at early clinical stage. Multiple exit opportunities exist with high impact & high ROI. The Company is seeking a supportive capital partner to maintain momentum up to $20M. Funding will be used to advance the lead drug through formal Investigational New Drug enabling studies towards New Drug Approval; estimating $3-5 Million now to advance into clinical studies. Preclinical / animal studies estimate ($3 - 5 Million and 12-18 months); follwed by potential combined Phase I-II clinical study in a rare cancer (approximately 2-3 years and $10M) to potential New Drug Approval, plus additional capital to advance additional drugs in the pipeline simultaneously, thus adding tremendous value to the Company's valuation. Valuations of pharma companies often exceed $100 Million valuation at Phase I (approx. 18 months), and New Drug Approval can exceed valuations above $1 Billion. The Company has numerous, improved high-impact cancer drugs advancing with proper support. NDA is required for comprehensive Confidential Information Memorandum crafted by ProNova Partners. Detailed Information Competition: Trying to improve existing therapies and develop novel approaches to hard to treat cancers. Growth & Expansion: Huge market potential. Financing: If the price and deal structure is right. Support & Training: Transition team included. Reason for Selling: Seeking supportive capital partners to take to the next level(s). .
Irvine, California
Medical Device Company - Biotech Patents
$ 4,000,000
The Company has proprietary technology that addresses a leading cause of maternal death (76,000) and fetal death (500,000) annually worldwide. 8% of pregnancies in the US and 14% worldwide have diagnoses that would be vastly improved by worldwide commercialization of the Company's proprietary device. A very low risk procedure that both provides quality of life improvement for the mother & baby and lowers health care costs is a win/win/win for all involved. Existing collaborations with major manufacturers coupled with a current expedited approval process with the FDA presents a tremendous opportunity for individuals or private equity groups seeking a transformative investment into a feel-good biotech story with exceptional legs and a vast runway with nearly unlimited upside. Able to work with groups/individuals in tranches of $500k to $1M to advance into the pilot clinical study, $2-$3MM for the pivotal clinical study towards market approval in the US. They will seek direct sales with partnered hospitals, licensing / partnership deals could utlimately yield the balance of funding to fully deploy a commercial version of the technology. NDA is required for comprehensive Confidential Information Memorandum (CIM) crafted by us. Detailed Information Competition: No current option available besides bed rest. Growth & Expansion: Huge market potential. Support & Training: Full team included. Reason for Selling: Seeking supportive capital partners to take to the next level(s). .
Recommended Brokers